# US 2012/0269839 A1 · Hmgn polypeptides as immune enhancers and hmgn antagonists as immune suppressants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269839 A1
- Document ID: US20120269839A1
- Status: Published application
- Kind: A1
- Application number: 13/533,492
- Filed: 2012-06-26
- Published: 2012-10-25
- Earliest claimed: 2008-07-25
- Assignees: The U.S.A. as represented by the Secretary,Depart. of Health and Human Services
- Inventors: De Yang; Joost J. Oppenheim; Michael Bustin
- Web page: https://patentgrep.com/patent/US20120269839A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 38/1709: {from mammals}
- A61K 39/00119: {Melanoma antigens}
- A61K 39/07: Bacillus
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- C12N 15/85: for animal cells
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C12N 2501/05: Adjuvants
- C12N 2501/23: Interleukins [IL]
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.

## Claims

### Claim 1

A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising HMGN1 (SEQ ID NO: 1), HMGN3a (SEQ ID NO: 2), HMGN3b (SEQ ID NO: 3), HMGN4 (SEQ ID NO: 4), Nsbp1 (SEQ ID NO: 5), or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response.

### Claim 2

A method of enhancing the activation or recruitment of dendritic cells in a host comprising administering to the host an HMGN polypeptide comprising HMGN1 (SEQ ID NO: 1), HMGN3a (SEQ ID NO: 2), HMGN3b (SEQ ID NO: 3), HMGN4 (SEQ ID NO: 4), Nsbp1 (SEQ ID NO: 5), or a functional fragment thereof, in an amount effective to enhance the activation or recruitment of dendritic cells in the host.

### Claim 3

A method of shifting the Th-1/Th-2 balance of an immune response of a host towards a Th-1 type immune response comprising administering to the host an HMGN polypeptide comprising HMGN1 (SEQ ID NO: 1), HMGN3a (SEQ ID NO: 2), HMGN3b (SEQ ID NO: 3), HMGN4 (SEQ ID NO: 4), Nsbp1 (SEQ ID NO: 5), or a functional fragment thereof, in an amount effective to shift the Th-1/Th-2 balance of an immune response towards a Th-1 type immune response.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method comprises administering to the host two or more different polypeptides, each comprising HMGN1 (SEQ ID NO: 1), HMGN3a (SEQ ID NO: 2), HMGN3b (SEQ ID NO: 3), HMGN4 (SEQ ID NO: 4), Nsbp1 (SEQ ID NO: 5), or functional fragment thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method comprises administering HMGN1 (SEQ ID NO: 1).

### Claim 6 (depends on 1)

The method of claim 1, wherein the HMGN polypeptide is administered by administering a nucleic acid encoding the HMGN polypeptide to the host.

### Claim 7 (depends on 1)

The method of claim 1 further comprising administering an antigen to the host.

### Claim 8 (depends on 7)

The method of claim 7, wherein the method comprises administering two or more different antigens to the host.

### Claim 9 (depends on 7)

The method of claim 7, wherein the antigen is a tumor antigen or microbial antigen.

### Claim 10 (depends on 9)

The method of claim 9, wherein the tumor antigen is a melanoma antigen.

### Claim 11 (depends on 9)

The method of claim 9, wherein the microbial antigen is an antigen derived from anthrax.

### Claim 12 (depends on 7)

The method of claim 7, wherein the antigen is administered by administering a nucleic acid encoding the antigen.

### Claim 13 (depends on 1)

The method of claim 1, wherein the host is a human.

### Claim 14

A pharmaceutical composition comprising
(a) an HMGN polypeptide comprising HMGN1 (SEQ ID NO: 1), HMGN3a (SEQ ID NO: 2), HMGN3b (SEQ ID NO: 3), HMGN4 (SEQ ID NO: 4), Nsbp1 (SEQ ID NO: 5), or a functional fragment thereof, and (b) an antigen;
or
(a) a nucleic acid encoding an HMGN polypeptide comprising HMGN1 (SEQ ID NO: 1), HMGN3a (SEQ ID NO: 2), HMGN3b (SEQ ID NO: 3), HMGN4 (SEQ ID NO: 4), Nsbp1 (SEQ ID NO: 5), or a functional fragment thereof, and (b) a nucleic acid encoding an antigen.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein (a) and (b) are provided as a fusion protein or conjugate, or nucleic acid encoding same.

### Claim 16 (depends on 14)

The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises two or more different HMGN polypeptides, each comprising HMGN1 (SEQ ID NO: 1), HMGN3a (SEQ ID NO: 2), HMGN3b (SEQ ID NO: 3), HMGN4 (SEQ ID NO: 4), Nsbp1 (SEQ ID NO: 5), or a functional fragment thereof.

### Claim 17 (depends on 14)

The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises HMGN1 (SEQ ID NO: 1).

### Claim 18 (depends on 14)

The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises a tumor antigen.

### Claim 19 (depends on 14)

The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises two or more different antigens.

### Claim 20

A method of suppressing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide antagonist in an amount effective to suppress an immune response, wherein the HMGN polypeptide comprises HMGN1 (SEQ ID NO: 1), HMGN3a (SEQ ID NO: 2), HMGN3b (SEQ ID NO: 3), HMGN4 (SEQ ID NO: 4), or Nsbp1 (SEQ ID NO: 5).
